2-benzyl-8-(cyclopentylmethyl)-6-(4-hydroxyphenyl)-7H-imidazo[1,2-a]pyrazin-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 2-benzyl-8-(cyclopentylmethyl)-6-(4-hydroxyphenyl)-7H-imidazo[1,2-a]pyrazin-3-one
• 化学式: C₂₅H₂₅N₃O₂
• 分子量: 399.5
• InChiKey: YEGCUOQUFAXCMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  64.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Full length kinase activity-conformation reporter
  申请人：UNIVERSITAT INNSBRUCK

  公开号：US11237173B2

  公开（公告）日：2022-02-01

  The present invention provides a reporter for a protein fragment complementation assay characterized in that the reporter is a fused protein comprising a first fragment, a second fragment and a protein kinase sequence section, wherein the first fragment and the second fragment are derived from different sections of the same split protein, and wherein the protein kinase sequence section intervenes between the first fragment and the second fragment and wherein the kinase sequence section comprises a kinase domain sequence and one or more regulatory sequence(s). Further the invention provides polynucleotides and cells encoding for the reporter as well as methods of conducting a protein fragment complementation assay with the reporter according to the invention.

  本发明提供了一种用于蛋白质片段互补检测的报告基因，其特征在于该报告基因是一种融合蛋白，包括第一片段、第二片段和蛋白质激酶序列部分，其中第一片段和第二片段来自同一分裂蛋白的不同部分，蛋白质激酶序列部分介于第一片段和第二片段之间，其中激酶序列部分包括激酶结构域序列和一个或多个调控序列。此外，本发明还提供了编码报告基因的多核苷酸和细胞，以及用本发明报告基因进行蛋白质片段互补检测的方法。
• FULL LENGTH KINASE ACTIVITY-CONFORMATION REPORTER
  申请人：UNIVERSITAT INNSBRUCK

  公开号：US20200033355A1

  公开（公告）日：2020-01-30

  The present invention provides a reporter for a protein fragment complementation assay characterized in that the reporter is a fused protein comprising a first fragment, a second fragment and a protein kinase sequence section, wherein the first fragment and the second fragment are derived from different sections of the same split protein, and wherein the protein kinase sequence section intervenes between the first fragment and the second fragment and wherein the kinase sequence section comprises a kinase domain sequence and one or more regulatory sequence(s). Further the invention provides polynucleotides and cells encoding for the reporter as well as methods of conducting a protein fragment complementation assay with the reporter according to the invention.
• US7396655B2
  申请人：——

  公开号：US7396655B2

  公开（公告）日：2008-07-08
• [EN] QUANTIFICATION OF AN INTERACTION BETWEEN A RAS PROTEIN AND A RAF PROTEIN<br/>[FR] QUANTIFICATION D'UNE INTERACTION ENTRE UNE PROTÉINE RAS ET UNE PROTÉINE RAF
  申请人：UNIVERSITÄT INNSBRUCK

  公开号：WO2017182437A1

  公开（公告）日：2017-10-26

  The present invention provides a method for quantification of an interaction between a Ras protein and a Raf protein, comprising the steps of a) providing a cell expressing two constructs for a protein-fragment complementation assay, wherein the first construct comprises the Ras protein and a first luciferase protein fragment, wherein the first luciferase protein fragment is located C-terminal from the Ras protein and wherein the second construct comprises the Raf protein and a second luciferase protein fragment, wherein the second luciferase protein fragment is located C-terminal from the Raf protein, wherein the second construct comprises a full-length Raf sequence section, and wherein the first and the second luciferase protein fragments are derived from different sections of the same luciferase protein b) allowing the first and second constructs to contact each other, c) providing a bioluminescence substrate for an intact luciferase protein and d) measuring for bioluminescence, wherein said bioluminescence indicates interaction between the two constructs upon reassembling of the first and second luciferase protein fragments.
• [EN] FUSION PROTEINS AND METHODS OF USING THE SAME FOR THE DETECTION OF NEUTRALIZING ANTIBODIES<br/>[FR] PROTÉINES DE FUSION ET LEURS PROCÉDÉS D'UTILISATION POUR LA DÉTECTION D'ANTICORPS NEUTRALISANTS
  申请人：[en]THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  公开号：WO2022170177A1

  公开（公告）日：2022-08-11

  Provided according to embodiments of the invention are fusion proteins comprising receptor binding domain polypeptides and receptor polypeptides linked to reporter enzyme fragments. The invention further relates to polynucleotides and vectors encoding the fusion proteins, cells comprising the fusion proteins, and methods of using the fusion proteins to study binding of test compounds, including identification of neutralizing antibodies, as well as diagnostic methods using the same.